Medication plan First-line A high-intensity statin is the standard starting point: Rosuvastatin 2040 mg daily, or Atorvastatin 4080 mg daily Expected goal: LDL reduction by at least 50% ideally much lower than current 209 If LDL is still above goal after 412 weeks Add: Ezetimibe 10 mg daily If still not controlled Consider: PCSK9 inhibitor or other advanced LDL-lowering therapy, especially if: LDL remains clearly elevated despite statin + ezetimibe there is suspected familial hypercholesterolemia coronary calcium / vascular disease is present statin intolerance occurs This escalation sequence is consistent with current guideline-based lipid management
GLP-1 Agonists Pipeline Development Activities The GLP-1 agonists therapeutics market report covers information on collaborations, acquisitions and mergers, licensing, and patent details for Glucagon-like Peptide-1 (GLP-1) Agonists
In June 2025, the European Medicines Agency officially recognized NAION as a very rare side effect of semaglutide after reviewing all data, concluding it may affect up to 1 in 10,000 people and recommending product information updates
You may lie down or rest if you experience dizziness, Nausea, flushing, or headaches
[Abstract]2026 Apr 16;33(4):523-537.e7
When you contact us, tell us what happened, when and where it happened, who was involved, and any documents you havethis information helps us quickly evaluate the type of case and the best ways to proceed
